ABSTRACT Benidipine, an L- and T-type calcium channel blocker, dilates both efferent and afferent arterioles and reduces glomerular pressure. Thus, it may exert renoprotective effects. We

conducted an open-labeled, randomized trial to compare the blood pressure (BP)-lowering effect and antiproteinuric effect of benidipine with those of amlodipine in hypertensive patients with

moderate-to-advanced-stage chronic kidney disease (CKD) (stages 3–5). These patients were already being administered the current maximum recommended doses of angiotensin receptor blockers

(ARBs). Patients with BP ⩾140/90 mm Hg, despite treatment with the maximum recommended dose of ARBs, were randomly assigned to two groups. The patients received either of the following

protein to creatinine ratio in the B group was significantly lower than that in the A group. Benidipine exerted antiproteinuric effect to a greater extent than did amlodipine, even in

patients with diabetic nephropathy. We conclude that the addition of benidipine, rather than amlodipine, ameliorates urinary protein excretion in hypertensive patients with CKD who are

already being administered ARBs. Therefore, we propose a combination therapy with benidipine and ARBs, even for patients with moderate-to-advanced-stage CKD. SIMILAR CONTENT BEING VIEWED BY

OTHERS COMPARISON OF THE EFFECTS OF ANGIOTENSIN RECEPTOR–NEPRILYSIN INHIBITORS AND THIAZIDE DIURETIC/RENIN–ANGIOTENSIN SYSTEM INHIBITOR COMBINATION THERAPY IN HYPERTENSIVE PATIENTS: A

RETROSPECTIVE COHORT STUDY Article 24 July 2023 CURRENT USE OF ANGIOTENSIN II RECEPTOR BLOCKERS AND ANGIOTENSIN-CONVERTING ENZYME INHIBITORS FOR HYPERTENSION IN PATIENTS WITH CHRONIC KIDNEY

DISEASE WITH PROTEINURIA: A CROSS-SECTIONAL STUDY BASED ON REAL-WORLD DATA Article 19 September 2024 ANTIHYPERTENSIVE EFFECTS AND SAFETY OF ESAXERENONE IN PATIENTS WITH MODERATE KIDNEY

DYSFUNCTION Article Open access 16 December 2020 INTRODUCTION On the basis of the results of several mega trials, including the MDRD (Modification of Diet in Renal Disease) study, a strict

control of blood pressure (BP) is recommended in hypertensive patients with chronic kidney disease (CKD).1 Proteinuria is one of the clinical parameters for diagnosing renal damage,

particularly in glomerular hypertension, and it has been reported to be a risk factor and predictor of cardiovascular events.2, 3 Therefore, suppression of proteinuria is a major goal in the

treatment of hypertensive patients with CKD. The renoprotective effects of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) have been shown

earlier.4, 5, 6 Blockade of the renin–angiotensin system (RAS) with ARBs or ACEIs is currently the most effective pharmacological tool for renoprotection. These agents reduce proteinuria

more effectively than other antihypertensive agents.7, 8 On the basis of these results, ARBs and ACEIs are recommended as first-choice drugs for the treatment of hypertensive patients with

CKD, according to the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004).9 However, it is difficult-to-control BP with monotherapy, particularly in

patients with CKD; this highlights the need for a combination drug therapy.10, 11 Calcium channel blockers (CCBs) reduce BP and are useful antihypertensive drugs. There are three types of

calcium channels: L-type calcium channels, which are distributed widely in smooth muscle cells of peripheral resistance arteries; N-type channels, which are located in the cells of the

brain; and T-type channels, which are localized to the sinus node and the brain. In renal tissues, the L-type calcium channels are present only in the afferent arterioles, whereas the N-type

and T-type calcium channels are localized in both efferent and afferent arterioles.12, 13 Amlodipine is a representative CCB that is used widely all over the world; it blocks the L-type

calcium channel and dilates the afferent arterioles to a higher degree than the efferent arterioles.14, 15 However, it has recently been reported that both a dual L-/N-type CCB cilnidipine

and an L-/T-type CCB efonidipine exhibit a greater antiproteinuric effect than does amlodipine.16, 17 Benidipine, another dual L-/T-type CCB, dilates both efferent and afferent arterioles

and reduces glomerular pressure.18 Therefore, benidipine also may exert renoprotective effects. However, few studies have reported the renoprotective effect of benidipine in hypertensive

patients with mild albuminuria.13, 19 The mechanism by which benidipine exerts renoprotective and antihypertensive effects in hypertensive patients with CKD has not been elucidated. The

objective of this study is to determine the effects of benidipine on BP and renoprotection in Japanese hypertensive patients with moderate-to-advanced stages of CKD (stages 3–5) and who are

already being treated with a maximum recommended dose of ARBs. METHODS This study was a 6-month-long, single-center, prospective, randomized, open-labeled clinical trial. It was designed to

compare the BP-lowering and antiproteinuric effects of benidipine and amlodipine in hypertensive patients with stage 3–5 CKD. These subjects were already being administered the maximum

recommended dose of ARBs. We obtained written informed consents for participation in the trial from all patients, and the protocol of the trial was approved by the ethics committee of our

institution. The study was conducted in accordance with the Declaration of Helsinki. The enrollment criteria for the subjects included: (1) hypertension that is, systolic and diastolic BP

⩾140/90 mm Hg, as measured in the sitting position on at least two separate visits to the clinics; (2) stage 3–5 CKD, as indicated by an estimated glomerular filtration rate (eGFR) of <60

 ml min−1 per 1.73 m2; (3) proteinuria, that is, urinary protein–creatinine (Cr) ratio ⩾300 mg g−1 (average of two consecutive measurements taken during a 4-week period before the

treatment); (4) treatment with the maximum recommended dose of an ARB (40 mg day−1 of olmesartan or 80 mg day−1 of telmisartan) for at least 8 weeks before the study. The exclusion criteria

were as follows: (1) age <20 years; (2) hypertensive emergency; (3) history of severe heart failure, angina, myocardial infarction or stroke within 6 months before the start of the trial;

(4) earlier treatment with steroids or immunosuppressants; (5) renovascular hypertension or endocrine hypertension; (6) severe diabetes mellitus that led to hospitalization because of

extremely high plasma glucose or that was associated with complications, such as diabetic ketoacidosis. The overview of the study design is shown in Figure 1. The subjects were randomly

assigned to two groups at the time of registration. An independent monitoring investigator, who did not treat the study subjects and who did not know the profile of the subjects before the

start of the trial, monitored randomization in the order of entry of the subjects; thereafter, the particulars of the assignments were delivered immediately to the individual investigators.

Dynamic balancing randomization was carried out on the basis of the serum Cr (sCr), urinary protein–Cr ratio measured at the time of registration and the presence or absence of diabetic

nephropathy. This was to ensure that there were no significant differences between the baseline characteristics of the two groups. The patients received either of the following treatment

regimens: 4 mg day−1 benidipine, which was increased to daily doses of 16 mg (B group), and 2.5 mg amlodipine, which was increased to daily doses of 10 mg (A group). Blood pressure was

measured in the outpatient clinic at fixed times after the medications were ingested. BP measurement was carried out according to the Japanese Society of Hypertension Guidelines for the

Management of Hypertension.9 On each monthly visit to the outpatient clinic, the BP was measured using a sphygmomanometer (Nippon Colin Co. Ltd., Tokyo, Japan); the measurements were carried

out twice with the patient in the sitting position after a 5-min rest. The patients were provided guidance on how to maintain their diet, particularly those following dietary restrictions.

The doses of the ARB and ACEI were not altered during the study period. The target BP level was <130/80 mm Hg. During the first 3 months of study, the patients were administered a

combination drug therapy with other conventional antihypertensive agents at baseline. However, if benidipine or amlodipine in combination with an RAS inhibitor failed to reduce the BP to the

target level within 3 months, additional antihypertensive medications (other than RAS inhibitors or CCBs) were administered to achieve the target BP. Withdrawal of drug treatment was

considered in patients who developed an allergy/intolerance to benidipine or amlodipine during the study period, developed a hypertensive emergency or showed any other condition or received

another therapy that, in the opinion of the investigators, might pose a risk for the patient or confound the results of the study. All the parameters that were used for monitoring the

effects of the drugs were evaluated once every month during the 24-week period of treatment. Laboratory values, such as sCr and potassium, were measured using commercial kits employing

routinely used clinical chemistry procedures. To assess urinary protein excretion, we measured the urinary concentrations of protein and Cr (protein–Cr ratio). Urinary protein was measured

using the pyrogallol red method. The treatment compliance and safety variables were checked at each visit to our hospital. The glomerular filtration rate (GFR) was estimated using the final

recommended modified equation for Japanese patients by the JSN-CKDI (Japanese Society of Nephrology-Chronic Kidney Disease Initiatives), because the eGFR obtained by this method is more

accurate for application in Japanese patients with CKD.20 The eGFR was calculated by the following formula: eGFR (ml min−1 per 1.73 m2)=194 × sCr−1.094 × Age−0.287( × 0.739 in the case of

women). STATISTICAL ANALYSIS Data were analyzed according to the randomly assigned groups of the participants, regardless of their subsequent medication status (intention-to-treat analysis),

and expressed as the mean±s.e.m. The baseline characteristics of the enrolled patients were tested to compare between the A and B groups using the unpaired _t_-test or Fisher's exact

test. The mean values in the two groups were compared using the unpaired _t_-test. Analysis of variance with repeated measurements and a subsequent multiple comparison test were applied to

test the effect of treatment on BP, heart rate and urinary protein–Cr ratio. Statistical significance was set at _P_<0.05. RESULTS BASELINE CHARACTERISTICS All the enrolled patients

(_n_=47) continued to participate in the study until the end of the trial. The baseline characteristics and medications administered to the subjects in the two groups are shown in Table 1.

No significant differences were observed between the two groups with regard to the baseline characteristics or the number of patients with diabetic nephropathy. Although the subjects were

not obese (mean body mass index of all subjects, 23.6±0.85 kg m−2), and their blood glucose and lipid levels at the baseline were well under control, adequate BP control was not achieved in

any of the enrolled patients. BP-LOWERING EFFECT Other antihypertensive agents listed in Table 1, such as ACE inhibitors and α-blockers, were administered throughout the trial period.

Furthermore, antihypertensive drugs other than ARBs or CCBs were administered additionally to four patients from the A group and to five patients from the B group during the study period (A

group: α-blocker, _n_=4; B group: furosemide, _n_=1; α-blocker, _n_=4). The final doses were 7.6±0.56 mg day−1 of amlodipine and 11.7±0.87 mg day−1 of benidipine in the A and B groups,

respectively. Figure 2 shows the changes in the systolic and diastolic BP. After treatment for 1 month, the systolic BP was significantly lower in the A group than in the B group, but no

such difference was observed at other time points. Diastolic BP did not differ between the two groups during the course of treatment. In the last month of treatment, no differences were

observed between systolic BP (A group: 133.4±1.3 mm Hg, B group; 136.1±1.8 mm Hg; not significant, NS) and diastolic BP levels (A group: 75.2±1.6 mm Hg, B group: 78.6±1.7 mm Hg; NS) in the

patients in the two groups. Patients with BP <140/90 mm Hg accounted for 65.2 and 58.3% of the patients in the A and B groups (NS), respectively. The recommended BP target (130/80 mm Hg)

was achieved in 43.4 and 37.5% of the total subjects of the A and B groups (NS), respectively. In both groups, the systolic and diastolic BP values were significantly lower than the baseline

values at 1 month after initiation of the CCB therapy. The heart rate did not differ between the two groups (A group: 74.6±2.3 beats min−1, B group: 76.1±2.2 beats min−1, NS).

RENOPROTECTIVE EFFECTS As shown in Figure 3, the sCr levels were increased significantly in both groups after 24 weeks of treatment; however, the difference between the increase noted in

both the groups was not significant. Furthermore, the eGFR levels were reduced significantly in both groups at the end of the study period. As shown in Figure 4, the urinary protein–Cr ratio

in the last month was significantly lower in the B group than in the A group (2565±299.9 _vs_. 3187±372.2 mg per gram Cr, _P_<0.05). The percentage reduction in urinary protein excretion

from the baseline showed a significant difference between the two treatment groups after 1 month of treatment and thereafter. Additionally, after 6 months of treatment, the percentage

change from the baseline value decreased in the B group but not in the A group; the values were significantly different between the two groups (−29.4±5.9 _vs_. −7.8±6.9%, _P_<0.05). Even

in a subgroup of patients with diabetic nephropathy, there was a significant difference in the percentage reduction in the urinary protein excretion from baseline values between the two

treatment groups. In addition, even in the subgroup with non-diabetic subjects, benidipine caused a significant reduction in the urinary protein–Cr ratio as compared with that caused by

amlodipine (Figure 5). ADVERSE EVENTS During the observation period, none of the patients in either group exhibited a significant increase in the occurrence of adverse effects, such as liver

impairment, skin rash or frequent urination. Furthermore, none of the patients required renal replacement therapy for hyperkalemia or progressive loss of renal function during the

observation period. DISCUSSION Treatment with an ACEI or ARB is recommended as the first-line therapy for achieving the target BP level in patients with CKD.9, 21, 22 However, monotherapy

with either of these drugs is effective in only a few patients; in most patients, two or three drugs with different mechanisms of action are required. The European Society of

Hypertension/European Society of Cardiology recommends a combination therapy of either ARB/diuretics or ARB/CCB for the management of difficult-to-control hypertension. Recently, it was

reported that the administration of a combination therapy with ARB and CCB exerted protective effects on organs in a rodent model.23, 24 Although CCBs and ARBs are considered first-line

antihypertensive drugs in Japan, the rate of attaining the target BP level by the administration of monotherapy with either drug is ∼12–40%.25, 26 According to a Japanese cross-sectional

survey, the combination therapy with a CCB and an ARB is the most prescribed treatment for hypertensive patients in Japan.26 Therefore, physicians frequently prescribe ARBs or ACEIs as

first-choice drugs and CCBs as second-choice drugs to hypertensive patients who have CKD with proteinuria. Recently, in the CARTER (Cilnidipine versus Amlodipine Randomized Trial for

Evaluation in Renal Disease) study, it was reported that, when coupled with an RAS inhibitor, treatment with cilnidipine—an L-/N-type CCB—was superior to treatment with amlodipine for the

prevention of the progression of proteinuria in hypertensive patients.16 However, the types and dosages of ARBs or ACEIs were not reported in the study. In this study, we showed that

benidipine is more beneficial than amlodipine as an additional medication for hypertensive patients with moderate-to-advanced-stage CKD associated with significant proteinuria (urinary

protein–Cr ratio >300 mg per gram Cr), and who are under treatment with the current maximum recommended dose of ARBs. In addition to RAS inhibition, a strict control of BP is considered

to be important for preventing the progression of CKD.21, 22, 27 In this study, the most consistent and statistically significant difference between the groups was in BP control: amlodipine

was more efficacious in reducing BP than benidipine, particularly during the first 1 month of treatment. Furthermore, although the reduction in BP level brought about by benidipine and

amlodipine was not statistically significant at the end of the study, BP levels tended to lower slightly in the amlodipine group than in the benidipine group (systolic–diastolic BPs were

133.4/75.2 _vs_. 136.1/78.6 mm Hg, A group _vs_. B group, respectively). Therefore, it might be possible that amlodipine, which is an L-type CCB, is beneficial in reducing systemic BP.

However, the antiproteinuric effect of benidipine was more than that of amlodipine, suggesting that benidipine, in addition to lowering the BP, has beneficial effects. The CARTER study

reported that the urinary protein–Cr ratio was lowered significantly after 12 months of treatment; however, in our study, it was reduced after 6 months of treatment. In another study, it was

reported that a higher urinary protein excretion (_P_<0.0001), lower GFR (_P_=0.0011) and the presence of diabetes (_P_=0.0284) correlated with the reduction of urinary proteins when the

treatment with amlodipine was replaced with treatment with benidipine.13 The difference between our study and the CARTER study could be attributed to the large number of diabetic

nephropathy cases included in our study. Moreover, the baseline proteinuria and sCr levels reflected a greater deterioration in patients in our study than in those of the CARTER study. These

differences may explain why the antiproteinuric effect was detected earlier in our study than in the CARTER study. Furthermore, the patients in our study were treated with the current

recommended maximum dose of ARBs for a considerably long time. Hence, the improvement in the glomerular hypertension on treatment with ARBs and benidipine resulted in a more pronounced

antiproteinuric effect. Some CCBs not only block the L-type calcium channels but also exert additional pleiotropic effects. CCBs that block either T-type or N-type calcium channels may exert

renoprotective effects by dilating the efferent artery and protecting the glomerulus from hyperfiltration injury.17, 28 Benidipine, which blocks the L- and T-type calcium channels,

decreases the resistance of the efferent and afferent arteries, and lowers the glomerular capillary hydrostatic pressure in rats.29 Therefore, benidipine, as well as cilnidipine may exert

renoprotective effects in hypertensive patients with CKD. The intraglomerular pressure is higher in patients with diabetic nephropathy than in patients with chronic glomerulonephritis or

hypertensive nephrosclereosis, and the number of patients with diabetic nephropathy in this study was high. Hence, it was considered that benidipine was more effective than amlodipine in the

case of diabetic patients. Our study is limited by the relatively small sample size and the short period of treatment. Moreover, although the prospective, randomized, open-label and

parallel-groups comparison design was used in this study, more longitudinal, double-blind, comparative multicenter clinical trials should be conducted in a larger number of patients in order

to further clarify the difference in the usefulness between the two agents; in addition to the BP profile, the percentage of renal replacement therapy requiring patients and other renal or

cardiovascular events should also be considered as endpoints. In our study, we noted that benidipine significantly reduced BP and the severity of proteinuria even when administered for only

a short duration. Therefore, we believe that this agent may be beneficial for hypertensive patients with stage 3–5 CKD. In conclusion, the administration of benidipine, rather than

amlodipine, ameliorates urinary protein excretion in hypertensive patients with moderate-to-advanced-stage CKD who are already being treated with ARBs. Therefore, we propose a combination

therapy with benidipine and ARBs even for patients with advanced-stage CKD. Moreover, the administration of this combination therapy might lead to the delay of the initiation of renal

replacement therapy. CONFLICT OF INTEREST The authors declare no conflict of interest. REFERENCES * Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S,

Massry SG, Seifter JL . The modification of diet in renal disease study group: blood pressure control, proteinuria, and the progression of renal disease. _Ann Intern Med_ 1995; 123: 754–762.

Article  CAS  Google Scholar  * De Leeuw PW, Thijs L, Birkenhager WH, Voyaki SM, Efstratopoulos AD, Fagard RH, Leonetti G, Nachev C, Petrie JC, Rodicio JL, Rosenfeld JJ, Sarti C, Staessen

JA, Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the

Syst-Eur trial. _J Am Soc Nephrol_ 2002; 13: 2213–2222. Article  Google Scholar  * Marin R, Gorostidi M, Fernandez-Vega F, Alvarez-Navascues R . Systemic and glomerular hypertension and

progression of chronic renal disease: the dilemma of nephrosclerosis. _Kidney Int_ 2005; 99: S52–S56. Article  Google Scholar  * Viberti G, Wheeldon MN, MicroAlbuminuria Reduction with

VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. _Circulation_ 2002; 106:

672–678. Article  CAS  Google Scholar  * Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of

angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. _N Engl J Med_ 2001; 345: 851–860. Article  CAS  Google Scholar  * Jafar TH, Stark PC, Schmid

CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS, AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and

angiotensin-converting enzyme inhibition, a patient-level meta-analysis. _Ann Intern Med_ 2003; 139: 244–252. Article  CAS  Google Scholar  * Weidmann P, Boehlen LM, Courten M . Effects of

different antihypertensive drugs on human proteinuria. _Nephrol Dial Transplant_ 1993; 8: 582–584. CAS  PubMed  Google Scholar  * Lavermann GD, Henning RH, De Jong PE, Navis G, Zeeuw D .

Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. _Am J Kidney Dis_ 2001; 38: 1381–1384. Article  Google Scholar  * Japanese Society of

Hypertension. Japanese Society of Hypertension Guidelines for Management of Hypertension (JSH 2004). _Hypertens Res_ 2006; 29 (Suppl): S1–S105. Article  Google Scholar  * Sheinfield GR,

Bakris GL . Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. _Am J Hypertens_ 1999; 12: 80–85. Article  Google Scholar  *

Waeber B . Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials. _J Hypertens_ 2006; 24: 19–27. Article  Google Scholar  * Hayashi K, Wakino

S, Homma K, Sugano N, Saruta T . Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation. _J Pharmacol Sci_ 2005; 99: 221–227.

Article  CAS  Google Scholar  * Ohishi M, Takagi T, Ito N, Terai M, Tatara Y, Hayashi N, Shiota A, Katsuya T, Rakugi H, Ogihara T . Renal-protective effect of T- and L-type calcium channel

blockers in hypertensive patients: an amlodipine-to-benidipine changeover (ABC) study. _Hypertens Res_ 2007; 30: 797–806. Article  CAS  Google Scholar  * Furukawa T, Yamakawa T, Midera T,

Sagawa T, Mori Y, Nukada T . Selectives of duhydropyridine derivatives in blocking Ca2+ channel subtypes expressed in Xenopus oocytes. _J Pharmacol Exp Ther_ 1999; 291: 464–473. CAS  PubMed

  Google Scholar  * Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T . Disparate effects of calcium antagonists on renal microcirculation. _Hypertens Res_ 1996; 19: 31–36. Article  CAS 

Google Scholar  * Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K, Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease(CARTER) Study

Investigators. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. _Kidney Int_ 2007;

72: 1543–1549. Article  CAS  Google Scholar  * Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ohta S, Yoshii M, Minami J, Ono H, Numabe A, Matsuoka H . Efonidipine reduces proteinuria and

plasma aldosterone in patients with chronic glomerulonephritis. _Hypertens Res_ 2007; 30: 621–626. Article  CAS  Google Scholar  * Morikawa T, Okumura M, Konishi Y, Okada N, Imanishi M .

Effects of benidipine on glomerular hemodyanamics and proteinuria in patients with nondiabetic nephropathy. _Hypertens Res_ 2002; 25: 571–576. Article  CAS  Google Scholar  * Saito F, Fujita

H, Takahashi A, Ichiyama I, Harasawa S, Oiwa K, Takahashi N, Otsuka Y, Uchiyama T, Kanmatsuse K, Kushiro T . Renoprotective effect and cost-effectiveness of using benidipine, a calcium

channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria. _Hypertens Res_ 2007; 30: 39–47. Article  CAS  Google Scholar  * The Japanese

Society of Nephrology. New eGFR equation for Japanese. Available at: http://www.jsn.or.jp/jsn_new/eng/index_e.html; accessed June 30, 2008. * Chobanian AV, Bakris GL, Black HR, Cushman WC,

Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and

Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection,

Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. _JAMA_ 2003; 289: 2560–2572. Article  CAS  Google Scholar  * European Society of Hypertension-European Society of

Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. _J Hypertens_ 2003; 21:

1011–1053. Article  Google Scholar  * Kim-Mitsuyama S, Izumi Y, Izumiyz Y, Yoshida K, Yoshiyama M, Iwao H . Additive beneficial effects of the combination of calcium channel blocker and an

angiotensin blocker on a hypertensive rat-heart failure model. _Hypertens Res_ 2004; 27: 771–779. Article  CAS  Google Scholar  * Suzuki J, Iwai M, Li Z, Li JM, Min LJ, Ide A, Yoshii T,

Oshita A, Mogi M, Horiuchi M . Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice. _J

Hypertens_ 2005; 23: 1383–1389. Article  CAS  Google Scholar  * Mancia G, Seravalle G, Grassi G . Tolerability and treatment compliance with angiotensin II receptor antagonists. _Am J

Hypertens_ 2003; 16: 1066–1073. Article  CAS  Google Scholar  * Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M, Umemura S . Current status of antihypertensive prescription and

associated blood pressure control in Japan. _Hypertens Res_ 2006; 29: 143–151. Article  CAS  Google Scholar  * Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G,

Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G,

Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa

M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka

F, Tamargo J, van Zwieten P, Waeber B, Williams B, Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the

Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European society of Cardiology (ESC).

_J Hypertens_ 2007; 25: 1105–1187. Article  CAS  Google Scholar  * Yue W, Kimura S, Fujisawa Y, Tian R, Li F, Rahman M, Nishiyama A, Fukui T, Abe Y . Benidipine dilates both pre- and

post-glomerular arteriole in the canine kidney. _Hypertens Res_ 2001; 24: 429–436. Article  CAS  Google Scholar  * Kawata T, Hashimoto S, Koike T . Diversity in the renal hemodynamic effects

of dihydropyridine calcium blockers in spontaneously hypertensive rats. _J Cardiovasc Pharmacol_ 1997; 30: 431–436. Article  CAS  Google Scholar  Download references AUTHOR INFORMATION

AUTHORS AND AFFILIATIONS * Division of Nephrology, Department of Medicine, Hypertension and Endocrinology, Nihon University School of Medicine, Tokyo, Japan Masanori Abe, Kazuyoshi Okada, 

Takashi Maruyama, Noriaki Maruyama & Koichi Matsumoto Authors * Masanori Abe View author publications You can also search for this author inPubMed Google Scholar * Kazuyoshi Okada View

author publications You can also search for this author inPubMed Google Scholar * Takashi Maruyama View author publications You can also search for this author inPubMed Google Scholar *

Noriaki Maruyama View author publications You can also search for this author inPubMed Google Scholar * Koichi Matsumoto View author publications You can also search for this author inPubMed

 Google Scholar CORRESPONDING AUTHOR Correspondence to Masanori Abe. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Abe, M., Okada, K., Maruyama, T. _et

al._ Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive

patients with stage 3–5 chronic kidney disease. _Hypertens Res_ 32, 270–275 (2009). https://doi.org/10.1038/hr.2009.11 Download citation * Received: 24 October 2008 * Revised: 25 December

2008 * Accepted: 12 January 2009 * Published: 27 February 2009 * Issue Date: April 2009 * DOI: https://doi.org/10.1038/hr.2009.11 SHARE THIS ARTICLE Anyone you share the following link with

will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt

content-sharing initiative KEYWORDS * angiotensin receptor blocker * benidipine * chronic kidney disease * proteinuria